Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Isoniazid
Drug ID BADD_D01204
Description Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status approved; investigational
ATC Code J04AC01
DrugBank ID DB00951
KEGG ID D00346
MeSH ID D007538
PubChem ID 3767
TTD Drug ID D09XQF
NDC Product Code 60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII V83O1VOZ8L
Synonyms Isoniazid | Isonicotinic Acid Hydrazide | Hydrazide, Isonicotinic Acid | Phthivazide | Phthivazid | Isonicotinic Acid Vanillylidenehydrazide | Acid Vanillylidenehydrazide, Isonicotinic | Vanillylidenehydrazide, Isonicotinic Acid | Ftivazide | Tubazide | Isonex
Chemical Information
Molecular Formula C6H7N3O
CAS Registry Number 54-85-3
SMILES C1=CN=CC=C1C(=O)NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tinnitus04.04.01.002; 17.04.07.004--
Toxic encephalopathy17.13.01.004; 12.03.01.0270.005560%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.018068%
Trismus17.01.03.004; 15.05.04.0040.002780%
Unresponsive to stimuli17.02.05.0310.002780%Not Available
Urinary incontinence17.05.01.008; 20.02.02.0100.002780%
Urticaria23.04.02.001; 10.01.06.001--
Vascular headache24.03.05.007; 17.14.01.005--Not Available
Vasculitis24.12.04.027; 10.02.02.0060.002780%
Vasculitis necrotising24.12.04.029; 10.02.02.0080.005560%Not Available
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.10.0130.006949%Not Available
Vitamin B6 deficiency14.12.02.0050.006949%Not Available
Vitamin D deficiency14.12.03.0030.002780%Not Available
Vomiting07.01.07.0030.060321%
Wheezing22.03.01.0090.004170%
Mental status changes19.07.01.0010.006949%Not Available
Tubulointerstitial nephritis20.05.02.0020.008339%Not Available
Postictal state19.13.01.005; 17.02.04.0140.002780%Not Available
Acute generalised exanthematous pustulosis12.03.01.005; 11.07.01.018; 10.01.01.034; 23.03.10.0020.002780%Not Available
Paradoxical drug reaction08.06.01.0140.011119%Not Available
Brain oedema17.07.02.003; 12.01.10.0100.008339%
Emotional distress19.04.02.008--Not Available
General physical health deterioration08.01.03.0180.005560%Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.0030.009729%Not Available
Haemodynamic instability24.03.02.0060.002780%Not Available
Fanconi syndrome acquired20.05.03.012; 14.01.01.0130.002780%Not Available
Epigastric discomfort07.01.02.004--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.004170%Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene